Broad-spectrum coverage is on your side
Tigecycline (Tygacil®) has in vitro activity against a wide range of range of pathogens1,2
Tigecycline is indicated in adults and in children from the age of 8 years for the treatment of complicated intra-abdominal infections and complicated skin and soft tissue infections excluding diabetic foot infections1
Tigecycline should be used only in situations where other alternative antibiotics are not suitable1
Tygacil® has broad in vitro* activity, including many resistant pathogens2
*In vitro activity does not necessarily correlate with clinical results.
†Except Proteus spp. and Providencia spp.
‡Includes MRSA and glycopeptide-resistant enterococci (GRE).
§Includes ESBL-producing bacteria and Acinetobacter spp. Please refer to SmPCs of individual antibiotics for specific coverage
Tigecycline (Tygacil ®) overcomes most known tetracycline resistance mechanisms3
Tigecycline inhibits bacterial protein synthesis in the 30S ribosomal subunit.1,4
is five times more stable binding with the ribosome than tetracycline3,4
overcomes the two major tetracycline resistance mechanisms (ribosomal protection and efflux pumps)1
is not affected by extended-spectrum beta-lactamases5
- Tygacil Summary of Product Characteristics
- Wilcox M H. Tigecycline and the need for a new broad-spectrum antibiotic class. Surg Infect (Larchmt) 2006;7:69-80
- Bauer G, Berens C et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004;53:592-599
- Bergeron J, Ammirati M et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996;40:2226-2228
- European Medicines Agency. Tygacil European public assessment report (EPAR) report. 2012 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_ _Scientific_Discussion/human/000644/WC500044511.pdf. Accessed August 2015